Transactions in which Mr. Pagnani has been involved include representations of:
- Alcon and its Independent Directors in the sale of Nestlé’s Alcon stake to Novartis and Novartis’ acquisition of the remaining publicly held minority interest in Alcon for $52.9 billion
- Bessemer Trust Company, as Trustee to the Louie E. Roche and Harvey Hubbell Trusts, in its reclassification by Hubbell Incorporated to eliminate its existing two-class structure
- Board of Directors of Andrx in its sale to Watson Pharmaceuticals
- Booking Holdings (f/k/a The Priceline Group) in its $1.2 billion acquisition of Getaroom from Court Square Capital Partners, $2.6 billion acquisition of OpenTable and $1.8 billion acquisition of KAYAK
- Brown Brothers Harriman in connection with Westrock Coffee Holdings’ $1.1 billion business combination with Riverview Acquisition Corp. and in its follow-on subscription for additional common stock of Westrock Coffee Company
- CA in its $590 million repurchase of its Common Stock from Careal Holding and acquisitions of Niku, Concord Communications and Netegrity
- Delta Air Lines in its agreement with Air France-KLM under which it acquired a 10% stake in Air France through a capital increase of $438 million
- Eastman Kodak in the sale of more than $3 billion of assets
- Endo International in its $2.6 billion acquisition of Auxilium Pharmaceuticals
- H&R Block in the sale of its financial advisory business to Ameriprise Financial
- Harris Corporation in its $35 billion merger of equals with L3 Technologies to form L3Harris Technologies and $4.6 billion acquisition of Exelis
- IMS Health in its sale of Erisco to the TriZetto Group and the subsequent sale of its TriZetto interest
- ING in the sale of its U.S. investment banking business to ABN Amro
- Kidde-Fenwal in the sale of substantially all of its assets and certain contributed assets of Carrier Group to an affiliate of Pacific Avenue Capital Partners
- L3Harris Technologies in the $800 million sale of its Commercial Aviation Solutions business to TJC, its approximately $1.96 billion acquisition of Viasat’s Tactical Data Links product line and the $1.05 billion sale of its Military Training business to CAE
- Lazard in its conversion from a publicly traded partnership to a U.S. C-Corporation under Delaware Law and changing its name from Lazard Ltd to Lazard, Inc.
- Linde on its delisting from the Frankfurt Stock Exchange by way of an Irish scheme of arrangement and a subsequent inter-company merger
- Pharmacia in its $60 billion merger with Pfizer
- Praxair in its $80 billion merger of equals with Linde AG
- Rabobank in its acquisition of Mid-State Bancshares
- Special Committee of Solera Holdings in its $6.5 billion acquisition by Vista Equity Partners
- Stryker in its $2.8 billion acquisition of Sage Products from Madison Dearborn Partners and acquisition of Stanmore Implants from SIW Holdings
- Special Committee of the Board of Directors of Teck Resources in the proposed spin-off of Teck’s steelmaking coal business, and the six-year sunset for the multiple voting rights attached to the Class A common shares of Teck
- UnitedHealth Group in Optum’s $3.7 billion pending acquisition of Amedisys, $6 billion merger with LHC Group, $13.8 billion acquisition of Change Healthcare, $4.3 billion acquisition of DaVita Medical Group and $12.8 billion combination with Catamaran; and its equity purchase agreement and related agreements relating to the sale of ClaimsXten to TPG Capital for $2.2 billion, tender offer for a 57% percent ownership in Empresas Banmédica and acquisitions of Sierra Health Services, Arnett HealthSystem and John Deere Healthcare
- Special Committee of Vertrue in its acquisition by One Equity Partners
Keith has represented Bank of America, Barclays Capital, Brown Brothers Harriman & Co., Centerview Partners, Citigroup, Goldman Sachs & Co., Greenhill & Co, Lazard Freres & Co., JPMorgan Chase & Co., Morgan Stanley, Oppenheimer & Co. and other investment banks in their capacity as financial adviser to the seller or buyer in connection with numerous transactions. Selected representations include advising the financial adviser in connection with the following M&A transactions:
- AmerisourceBergen’s $2.5 billion acquisition of MWI Veterinary Supply
- Board of Directors of Beacon in its $11 billion pending acquisition by QXO
- The Beneficient Company Group’s $3.5 billion merger with Avalon Acquisition
- Brookfield Property Partners’ (“BPY”) special committee in connection with Brookfield Asset Management’s $6.5 billion acquisition of BPY
- Coca-Cola Enterprises’ merger of Coca-Cola Iberian Partners and Coca-Cola Erfrischungsgetränke to form Coca-Cola European Partners
- Fresenius’ acquisition of APP Pharmaceuticals
- General Motors’ spin-off of Hughes Defense business
- Patterson Companies’ $1.1 billion acquisition of Animal Health International
- Mallinckrodt in its $6.7 billion pending combination with Endo
- PeopleSoft’s defense against and ultimate sale to Oracle
- St. Jude Medical’s $3.3 billion acquisition of Thoratec
- Starwood Hotels’ $12 billion acquisition by Marriott International
- Taubman Centers’ defense against Simon Property Group’s hostile offer
